Literature DB >> 15862315

A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells.

Shuichi Yoshihara1, Atsushi Kon, Daisuke Kudo, Hideaki Nakazawa, Ikuko Kakizaki, Mutsuo Sasaki, Masahiko Endo, Keiichi Takagaki.   

Abstract

4-Methylumbelliferone (MU) inhibits the cell surface hyaluronan (HA) formation, and that such inhibition results in suppression of adhesion and locomotion of cultured melanoma cells. Here, we examine the effect of MU on melanoma cell metastasis in vivo. MU-treated melanoma cells showed both decreased cell surface HA formation and suppression of liver metastasis after injection into the mice. Oral administration of MU to mice decreased tissue HA content. These HA knock-down mice displayed suppressed liver metastasis. Thus, both cell surface HA of melanoma cells and recipient liver HA can promote liver metastasis, indicating that MU has potential as an anti-metastatic agent.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15862315     DOI: 10.1016/j.febslet.2005.03.079

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  42 in total

1.  Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells.

Authors:  Vinata B Lokeshwar; Luis E Lopez; Daniel Munoz; Andrew Chi; Samir P Shirodkar; Soum D Lokeshwar; Diogo O Escudero; Neetika Dhir; Norman Altman
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

2.  Improving the distribution of Doxil® in the tumor matrix by depletion of tumor hyaluronan.

Authors:  Aditya G Kohli; Saul Kivimäe; Matthew R Tiffany; Francis C Szoka
Journal:  J Control Release       Date:  2014-05-20       Impact factor: 9.776

3.  Inhibition of Stabilin-2 elevates circulating hyaluronic acid levels and prevents tumor metastasis.

Authors:  Yoshikazu Hirose; Eiko Saijou; Yasuyoshi Sugano; Fumitaka Takeshita; Satoshi Nishimura; Hidenori Nonaka; Yen-Rong Chen; Keisuke Sekine; Taketomo Kido; Takashi Nakamura; Shigeaki Kato; Toru Kanke; Koji Nakamura; Ryozo Nagai; Takahiro Ochiya; Atsushi Miyajima
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-27       Impact factor: 11.205

4.  Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting.

Authors:  Shuangshuang Song; Huan Qi; Jingwen Xu; Pan Guo; Fen Chen; Fei Li; Xinggang Yang; Naicheng Sheng; Yingliang Wu; Weisan Pan
Journal:  Pharm Res       Date:  2014-05-20       Impact factor: 4.200

5.  Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look.

Authors:  Clifford J Whatcott; Haiyong Han; Richard G Posner; Galen Hostetter; Daniel D Von Hoff
Journal:  Cancer Discov       Date:  2011-09       Impact factor: 39.397

6.  Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells.

Authors:  Hiroshi Okuda; Aya Kobayashi; Bo Xia; Misako Watabe; Sudha K Pai; Shigeru Hirota; Fei Xing; Wen Liu; Puspa R Pandey; Koji Fukuda; Vishnu Modur; Arnab Ghosh; Andrew Wilber; Kounosuke Watabe
Journal:  Cancer Res       Date:  2011-11-23       Impact factor: 12.701

7.  Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.

Authors:  Anaid Benitez; Travis J Yates; N Shamaldevi; Tim Bowen; Vinata B Lokeshwar
Journal:  J Urol       Date:  2012-12-07       Impact factor: 7.450

Review 8.  Carcinoma Cell Hyaluronan as a "Portable" Cancerized Prometastatic Microenvironment.

Authors:  Eva A Turley; David K Wood; James B McCarthy
Journal:  Cancer Res       Date:  2016-04-20       Impact factor: 12.701

9.  Hyaluronan synthesis inhibitor supplements the inhibitory effects of zoledronic acid on bone metastasis of lung cancer.

Authors:  Naohisa Futamura; Hiroshi Urakawa; Eisuke Arai; Eiji Kozawa; Naoki Ishiguro; Yoshihiro Nishida
Journal:  Clin Exp Metastasis       Date:  2013-01-04       Impact factor: 5.150

Review 10.  Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction.

Authors:  Clifford J Whatcott; Haiyong Han; Daniel D Von Hoff
Journal:  Cancer J       Date:  2015 Jul-Aug       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.